What's Happening?
Bausch + Lomb Corporation announced the results of its Phase 2 study evaluating the neuroprotective candidate BL1107 for glaucoma patients. The study did not meet its primary endpoint of improving visual function, as observed in a smaller Phase 1/2a study.
Consequently, the company has decided to discontinue the development of BL1107 as a topical eye drop for glaucoma. Despite this setback, Bausch + Lomb will continue to focus on developing a sustained-release implant for geographic atrophy, a vision-threatening disease. The company acquired Whitecap Biosciences in 2025 to advance this implant, which is expected to enter clinical trials in 2028. The study involved 159 adults with primary open-angle glaucoma or ocular hypertension, but failed to achieve key secondary endpoints related to visual function improvements.
Why It's Important?
The decision to halt the development of BL1107 as an eye drop underscores the challenges in drug development, particularly in the field of ophthalmology. Bausch + Lomb's diversified approach to innovation, which includes a broad portfolio of over 60 assets, allows the company to pivot and focus on other promising treatments. The sustained-release implant for geographic atrophy represents a significant opportunity, as it addresses a critical unmet need in eye health. This strategic shift could have implications for patients with geographic atrophy, potentially offering a new treatment option in the future. The company's ability to adapt and refocus its resources highlights the importance of maintaining a diverse pipeline in the pharmaceutical industry.
What's Next?
Bausch + Lomb plans to continue its collaboration with Ripple Therapeutics to develop the sustained-release implant for geographic atrophy. Clinical trials for this implant are anticipated to begin in 2028. The company will also continue to pursue other assets within its portfolio, aiming to achieve multiple clinical, regulatory, and commercial milestones in the coming years. This ongoing development could lead to new treatment options for various eye conditions, supporting Bausch + Lomb's mission to improve eye health globally.
